학술논문
Recurrent pneumothorax in a patient with liposarcoma as either a complication of lung micrometastasis or a potential adverse event from antibiotic therapy: A case report
Document Type
Academic Journal
Author
Source
Oncology Letters. July, 2022, Vol. 24 Issue 1, p1d, p7 p.
Subject
Language
English
ISSN
1792-1074
Abstract
Spontaneous pneumothorax (PNX) is an infrequent manifestation of primary lung cancer, soft tissue sarcoma and metastasis. There are no easily accessible data in the literature regarding the correlation between PNX and antibiotics, whereas cases of PNX following chemotherapy have been observed. Only 1-10% of treatment-related adverse events are estimated to be reported to the Food and Drug Administration. The present study described a case of PNX of the left lung in a 70-year-old treatment-naive patient with retroperitoneal liposarcoma. The PNX developed after 8 days of treatment with levofloxacin and after 6 days of piperacillin/tazobactam treatment for a suspicious inflammatory area in the right lung detected by an FDG-PET scan before the patient started chemotherapy. A chest CT scan confirmed the presence of metastasis in the right lung, but neither FDG-PET/CT nor CT showed metastatic disease in the left lung. A total of 14 days after the end of the third cycle of doxorubicin (2 months after the initial diagnosis of PNX), the patient manifested a massive PNX of the right lung. In conclusion, these findings indicated that spontaneous PNX could be linked to the use of some antibiotics.
Introduction Pharmacovigilance plays an important role in evaluating, monitoring and preventing adverse drug reactions (ADRs) (1). Although randomized clinical trials are acknowledged as the gold standard to assess the efficacy [...]
Introduction Pharmacovigilance plays an important role in evaluating, monitoring and preventing adverse drug reactions (ADRs) (1). Although randomized clinical trials are acknowledged as the gold standard to assess the efficacy [...]